Oxford Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Oxford Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-34,133	Closed	-$371K	–	1927
2019 Q3	$371K	Buy	+34,133	New	+$372K	0.01%	1376
2018 Q4	–	Sell	-42,812	Closed	-$612K	–	1948
2018 Q3	$612K	Buy	+42,812	New	+$592K	0.01%	1228
2015 Q1	–	Sell	-15,799	Closed	-$223K	–	705
2014 Q4	$223K	Sell	15,799 -34,037	-68%	-$440K	﹤0.01%	621
2014 Q3	$621K	Buy	+49,836	New	+$622K	0.01%	523
2014 Q1	–	Sell	-29,935	Closed	-$363K	–	702
2013 Q4	$363K	Sell	29,935 -32,977	-52%	-$394K	0.01%	614
2013 Q3	$768K	Buy	62,912 +13,926	+28%	+$194K	0.02%	605
2013 Q2	$647K	Buy	+48,986	New	+$677K	0.02%	659

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Oxford Asset Management's LFCR Position: Q4 2019 in Review

Oxford Asset Management sold out of Lifecore Biomedical (LFCR) in Q4 2019, closing a stake of 34,133 shares — an estimated $371K sold.

Oxford Asset Management first reported a position in LFCR in Q2 2013 and held it in 7 quarters. The position peaked at $768K in Q3 2013. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2019.

Oxford Asset Management reported no remaining Lifecore Biomedical position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 34,133 Lifecore Biomedical shares in Q4 2019, an estimated $371K.
Oxford Asset Management first reported a position in Lifecore Biomedical in Q2 2013 and held it in 7 quarters.
Oxford Asset Management's Lifecore Biomedical position peaked at $768K in Q3 2013.
93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.